Stifel Reiterates Buy Rating on Pliant Therapeutics (PLRX)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. SMCI
6. GOOGL
7. RTX
8. COF
9. TSLA
10. CRWV

Go back to Stifel Reiterates Buy Rating on Pliant Therapeutics (PLRX)

Pliant Therapeutics (PLRX) PT Lowered to $45 at Oppenheimer

August 8, 2024 8:00 AM EDT

Oppenheimer analyst Jeff Jones lowered the price target on Pliant Therapeutics (NASDAQ: PLRX) to $45.00 (from $48.00) while maintaining a Outperform rating.... More

Pliant Therapeutics, Inc. (PLRX) Misses Q2 EPS by 7c

August 8, 2024 4:08 AM EDT

Pliant Therapeutics, Inc. (NASDAQ: PLRX) reported Q2 EPS of ($0.92), $0.07 worse than the analyst estimate of ($0.85).

For earnings history and earnings-related data on Pliant Therapeutics, Inc. (PLRX) click here.

... More